SEATTLE, Feb. 15, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today the appointment of H. Stewart Parker as its new Chief Executive Officer and new member of the IDRI board of directors. Parker is a widely recognized figure in the biotechnology industry, having served as President and CEO of Targeted Genetics Corp. and, formerly, Vice President, Corporate Development at Immunex Corp.
"I look forward to working with Stewart, who represents a balance of entrepreneurial spirit and operational expertise," said Steve Reed, IDRI's Founder and Head of Research and Development.
"I couldn't be more thrilled to join IDRI. The organization possesses a number of technologies that may have an enormous impact on the health of the world," indicated Parker. "To support their innovation, IDRI possesses developmental capabilities that are rare in non-profits ― yet urgently needed if global health funding is going to result in products that make a difference."
Currently a Commercialization Consultant with the Washington Biotechnology & Biomedical Association (WBBA), Parker sits on a number of boards including OncoGenex and C3 Jian Inc. Parker was a long-term board member of Biotechnology Industry Organization (BIO). She earned an MBA from the University of Washington Foster School of Business.
"The board conducted an exhaustive international search as we sought the best candidate to lead IDRI," says Franklyn Prendergast, M.D., Ph.D. "Stewart's strength and status as a highly respected CEO made her a unique fit with IDRI's team, as well as with our core values and mission."
The appointment follows the announcement of several new grants that ensures IDRI's continuing success in the area of vaccine development, drug discovery, and diagnostics.
About IDRI – Translating science into global health solutions
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.
For more information, go to www.idri.org.
|SOURCE Infectious Disease Research Institute (IDRI)|
Copyright©2010 PR Newswire.
All rights reserved